Vinci Compass Investments Ltd. (NASDAQ: VINP) ("Vinci Compass," "the Company," "we," "us," or "our"), the controlling company of a leading alternative investments and global solutions provider in ...

Before a former YouTuber faced off with a former heavyweight champion, two former mixed martial arts champions did battle in a boxing ring. Anderson Silva, at age 50, sent Tyron Woodley to a 0-3 pro ...

March 2026 arrives at a rare and drastic inflection point, as the global landscape undergoes a shift so volatile that the very state of world affairs feels caught in a permanent flux. And in this ...

Like most old skills, there's something deeply satisfying about getting where you want to go with the humble compass. I remember the feeling of accomplishment upon completing a 10-mile crossing in ...

Subscribe Login Register Log out My Profile Subscriber Services Search PGe NEWSLETTERS PG STORE ARCHIVES PUBLIC NOTICES OBITUARIES JOBS CLASSIFIEDS EVENTS PETS ...

Lawmakers urge DOJ to detail its review of the $1.6B Compass-Anywhere merger, citing risks to competition and housing costs. The lawmakers say the letter comes after reports that former assistant ...

Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome. Results included maintaining a ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the British biotech’s share price up 30% and teeing up talks about filing for ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical Officer Guy Goodwin. By providing 26 weeks’ worth of such data instead of the ...

A psychedelic medicine for hard-to-treat depression could be under approval review before the end of this year, now that its developer has scored positive data from another large clinical trial.